Pech V, Thumova M, Dikalov SI, Hummler E, Rossier BC, Harrison DG, Wall SM. Nitric oxide reduces Cl Ϫ absorption in the mouse cortical collecting duct through an ENaC-dependent mechanism. Am J Physiol Renal Physiol 304: F1390 -F1397, 2013. First published March 20, 2013 doi:10.1152/ajprenal.00292.2012.-Since nitric oxide (NO) participates in the renal regulation of blood pressure, in part, by modulating transport of Na ϩ and Cl Ϫ in the kidney, we asked whether NO regulates net Cl Ϫ flux (JCl) in the cortical collecting duct (CCD) and determined the transporter(s) that mediate NOsensitive Cl Ϫ absorption. Cl Ϫ absorption was measured in CCDs perfused in vitro that were taken from aldosterone-treated mice. Administration of an NO donor (10 M MAHMA NONOate) reduced J Cl and transepithelial voltage (VT) both in the presence or absence of angiotensin II. However, reducing endogenous NO production by inhibiting NO synthase (100 M N G -nitro-L-arginine methyl ester) increased J Cl only in the presence of angiotensin II, suggesting that angiotensin II stimulates NO synthase activity. To determine the transport process that mediates NO-sensitive changes in J Cl, we examined the effect of NO on J Cl following either genetic ablation or chemical inhibition of transporters in the CCD. Since the application of hydrochlorothiazide (100 M) or bafilomycin (5 nM) to the perfusate or ablation of the gene encoding pendrin did not alter NO-sensitive J Cl, NO modulates JCl independent of the Na ϩ -dependent Cl Ϫ /HCO 3 Ϫ exchanger (NDCBE, Slc4a8), the A cell apical plasma membrane H ϩ -ATPase and pendrin. In contrast, both total and NO-sensitive J Cl and VT were abolished with application of an epithelial Na ϩ channel (ENaC) inhibitor (3 M benzamil) to the perfusate. We conclude that NO reduces Cl Ϫ absorption in the CCD through a mechanism that is ENaC-dependent. nitric oxide; transepithelial voltage; cortical collecting duct ALDOSTERONE AND ANGIOTENSIN II increase NaCl absorption in the cortical collecting duct (CCD) by stimulating transporters such as epithelial Na ϩ channel (ENaC) and pendrin (12, 21, 24, 28, 39, 40) , which increases NaCl absorption, thereby contributing to the hypertension expected following treatment with these hormones (41, 44) .
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In vascular and in renal tissue, many of the effects of angiotensin II and aldosterone are mediated by changes in O 2 ·Ϫ /H 2 O 2 or nitric oxide (NO) (1, 11, 19, 23, 48, 49) . In kidney cells, aldosterone stimulates ENaC activity, in part, by increasing O 2 ·Ϫ production and by reducing NO bioavailability (52) . With increased NO bioavailability, a natriuresis and diuresis are observed (20) due to inhibition of renal Na ϩ transporters, such as ENaC (33) . However, NO may also reduce Cl Ϫ absorption by inhibiting pendrin since NO reduces HCO 3 Ϫ secretion in rabbit CCD (37) and since HCO 3 Ϫ secretion occurs largely through pendrin-dependent transport (31) . Thus, the purpose of this study was to determine whether NO reduces Cl Ϫ absorption in the mouse CCD and to explore the transport mechanism(s) by which this occurs.
METHODS

Animals. All experiments were performed on male and female
Slc26a4
Ϫ/Ϫ (or Pds Ϫ/Ϫ ) mice developed by Everett et al. (4) and in wild-type mice from the same strain (129S6/SvEv Tac; Taconic Farms), which were bred in parallel. Every third generation wild-type and pendrin-null mice were interbred to produce heterozygotes. These heterozygotes were interbred to generate new wild-type and homozygous pendrin-null breeders (25) .
We generated mice that were both homozygous pendrin-null and homozygous for the Liddle's mutation (29) (Pds Ϫ/Ϫ & L/L), which constitutively upregulates the ENaC. To do so, mice homozygous for the Liddle's mutation (29) on a C57Bl6 background were bred with homozygous pendrin-null mice (4) on a 129S6SvEvTac background. The progeny were backcrossed onto a 129 S6SvEvTac background over at least 10 generations. Mouse genotype was determined from tail biopsies using real-time PCR with specific probes designed for each gene (Transnetyx, Cordova, TN).
For 5-7 days before death, mice ate a balanced diet (53881300; Zeigler Brothers) prepared as a gel (0.6% agar, 74.6% water, and 24.8% mouse chow) supplemented with NaCl (ϳ0.8 meq NaCl/day) (12) and were treated with aldosterone by minipump (250 g·kg body wt Ϫ1 ·day Ϫ1 ). The Institutional Animal Care and Use Commmittee at Emory University approved all treatment protocols.
In vitro perfusion of isolated CCDs. CCDs were dissected from medullary rays and perfused at flow rates of 2-3 nl/min in the presence of symmetric, physiological solutions containing (in mmol/l) 125 NaCl, 2.5 K 2HPO4, 24 NaHCO3/5% CO2, 2 CaCl2, 1.2 MgSO4, and 5.5 glucose bubbled with 95% air-5% CO2 (31) . Unless otherwise stated, 10 nM angiotensin II was present in the bath solution (24) . Tubules were equilibrated at 37°C for 30 min before the collections were started. Stock solutions of benzamil hydrochloride (3 ϫ 10 Ϫ3 M) were prepared in deionized water. Hydrochlorothiazide stock solutions (10 Ϫ1 M) were prepared in DMSO, whereas stock solutions of bafilomycin (10 Ϫ5 M) were prepared in absolute ethanol. All chemicals were purchased from Sigma (St. Louis, MO). MAHMA NONOate was purchased from Axxora (San Diego, CA). Stock solutions of 20 mM MAHMA were prepared in 0.01 M NaOH and used within 24 h. Uric acid was prepared in 1 M NaOH, diluted 1:1,000, and then titrated to pH 7.4 with 1 M HCl. Stock solutions of tempol and N G -nitro-L-arginine methyl ester (L-NAME) were made in deionized water and diluted 1:1,000.
Measurement of net transepithelial Cl
Ϫ flux. Cl Ϫ concentration was measured in perfusate and collected samples using a continuousflow fluorimeter and the Cl Ϫ -sensitive fluorophore 6 methoxy-N-(3-sulfopropyl) quinolinium (Molecular Probes, Eugene, OR), as described previously (5, 43, 44) . Transepithelial Cl Ϫ flux (JCl) was calculated according to the equation: JCl ϭ (Co Ϫ CL)Q/L, where Co and CL are perfusate and collected fluid Cl Ϫ concentrations, respectively. Q is flow rate in nanoliters per minute. L is tubule length. Net fluid transport was taken to be 0 since net fluid flux was observed in CCDs when perfused in vitro in the presence of symmetric solutions and in the absence of vasopressin (13, 14) . J Cl was expressed in picomoles per millimeter per minute.
Transepithelial voltage (V T) was measured in the perfusion pipette connected to a high-impedance electrometer through an agar bridge saturated with 0.16 M NaCl and a calomel cell as described previously (42) . The reference was an agar bridge from the bath to a calomel cell.
Statistics. All data are presented as means Ϯ SE. Data displayed usually represented a single measurement. Occasionally, data from two collections were averaged to obtain a single value. Each "n" used in the statistical analysis represents data from separate mice. To test for statistical significance between two groups, a paired or an unpaired Student's t-test was used, as appropriate. The criterion for statistical significance was P Ͻ 0.05.
RESULTS
NO reduces Cl
Ϫ absorption. We examined the effect of NO donors on Cl Ϫ absorption in CCDs from aldosterone-treated mice that were perfused in vitro with angiotensin II (10 nM) in the bath solution. Aldosterone was applied in vivo and angiotensin II was applied in vitro to upregulate the ENaC (21, 28) , the H ϩ -ATPase (27, 50) , and pendrin (24, 39) . As shown, while 1 M MAHMA NONOate did not alter J Cl or V T (Fig. 1, A and  B) , application of 10 M MAHMA NONOate reduced J Cl and V T by ϳ50% (Fig. 1, C and D) . This fall in J Cl and V T was not due to time-dependent changes ( Fig. 1, E and F) . To determine whether MAHMA reduces Cl Ϫ absorption through a breakdown product of MAHMA, Cl Ϫ absorption was measured before and after the addition of MAHMA that had been allowed to decay (Fig. 1, G and H) . As shown, decayed MAHMA did not change J Cl or V T . We conclude that MAHMA reduces Cl Ϫ absorption through a direct effect of NO.
Further experiments asked whether reducing endogenous production of NO alters Cl Ϫ absorption. Thus, Cl Ϫ absorption was measured in the presence and absence of the NO synthase (NOS) inhibitor L-NAME (100 M; Fig. 2 ) with angiotensin II in the bath solution. As shown, Cl Ϫ absorption increased ϳ30% with L-NAME application, although V T did not change significantly.
Angiotensin II increases NO production in vascular tissue by stimulating NOS activity (7, 10, 30, 32) and stimulates NADPH oxidase activity, thereby increasing the production of O 2 ·Ϫ (17, 34) . Since impaired O 2 ·Ϫ /NO balance in the CCD may alter the response to NO donors or NOS inhibitors, we examined the effect of NO donors and NOS inhibitors on Cl Ϫ absorption in the absence of angiotensin II. As shown (Fig. 3) , following NO donor (10 M MAHMA) application, Cl Ϫ absorption fell 64% (n ϭ 3, P Ͻ 0.05), while V T fell 47% (n ϭ 3, P Ͻ 0.05) similar to the effects observed in the presence of angiotensin II. Therefore, NO donors modulate J Cl both in the presence and in the absence of angiotensin II. In contrast, while NOS inhibition increased Cl Ϫ absorption in the presence of angiotensin II (Fig.  2) , in the absence of angiotensin II, NOS inhibition (100 M L-NAME; Fig. 4 ) did not change Cl Ϫ absorption. We conclude that Cl Ϫ flux is much more sensitive to NOS inhibition following angiotensin II application in vitro, likely because angiotensin II increases NO production by stimulating NOS activity.
Since superoxide (O 2
·Ϫ
) is involved in the breakdown of endothelium-derived vascular relaxing factor (NO) (6), we explored the effect of reducing O 2 ·Ϫ through the application of a superoxide dismutase mimetic (50 M tempol) to the bath. As shown (Fig. 5 ), tempol did not reduce Cl Ϫ absorption in CCDs from aldosterone-treated mice, when perfused either in the presence or in the absence of angiotensin II in the bath solution. To exclude the possibility that tempol failed to reduce Cl Ϫ absorption because of limited intracellular accumulation, we examined the effect of tempol in an unpaired experiment, in which CCDs were exposed to tempol for a longer period of time (i.e., at least 30 min) before each collection was started. Tubules were perfused in the presence of angiotensin II to stimulate O 2 ·Ϫ production. Although Cl Ϫ absorption was numerically lower with tempol present in the bath, the difference did not reach statistical significance (Fig. 5) (Fig. 7,  A and B) . As shown, luminal bafilomycin did not eliminate MAHMA-induced changes in J Cl and V T . We conclude that 1 Although we could not demonstrate a significant role for O2 ·Ϫ in Cl , and reduced VT from Ϫ28.4 Ϯ 2.6 to Ϫ14.9 Ϯ 2.9 mV, respectively.
MAHMA does not reduce J Cl by inhibiting the apical plasma membrane H ϩ -ATPase. Bafilomycin might not modify the effect of NO donors on J Cl either because the H ϩ -ATPase is not sensitive to this NO donor or because the H ϩ -ATPase does not play a significant role in Cl Ϫ absorption in this treatment model. To resolve this question, we measured Cl Ϫ absorption in the CCD, in the presence and absence of the H ϩ -ATPase inhibitor bafilomycin (5 nM) in the perfusate. As shown (Fig. 7, C and D) , bafilomycin did not change J Cl or V T . We therefore conclude that inhibiting the apical H ϩ -ATPase does not significantly alter Cl Ϫ absorption in CCDs from aldosterone-treated mice.
In the CCD of NaCl-restricted mice, Cl Ϫ absorption occurs through a thiazide-sensitive Na Figure 8 demonstrates that thiazides do not block the fall in Cl Ϫ absorption and V T observed with the application of NO donors. Because thiazides do not eliminate NO-sensitive changes in J Cl , Slc4a8 is not likely a significant target of NO in CCDs from aldosterone-treated mice. These observations are in agreement with a recent study demonstrating that the thiazide-sensitive component of Cl Ϫ absorption is very low in CCDs taken from mice following aldosterone treatment (26) .
To determine whether NO targets ENaC-dependent Cl Ϫ absorption, we tested whether NO donors modulate the benzamil-sensitive component of Cl Ϫ absorption. We observed that with an ENaC inhibitor (benzamil) in the perfusate, Cl Ϫ absorption and V T are low and unchanged with MAHMA application (Fig. 9, A and B) . Moreover, in the presence of an ENaC inhibitor (benzamil), NOS inhibitors (L-NAME) did not stimulate Cl Ϫ absorption or V T (Fig. 9, C and D) . We conclude that NO reduces Cl Ϫ absorption through a benzamil-sensitive pathway that depends on the epithelial Na ϩ channel. question, we tested the effect of pendrin gene ablation (Slc26a4) on NO-sensitive Cl Ϫ absorption. As shown, pendrin gene ablation did not eliminate the increase in Cl Ϫ absorption observed with NOS inhibitor (100 M L-NAME; Fig. 10) application. These data suggest that NO regulates J Cl independent of pendrin. In contrast, pendrin gene ablation eliminated the fall in Cl Ϫ absorption observed with NO donor administration (Fig. 11, A and B) . Why Cl Ϫ absorption changed with the application of a NOS inhibitor but not with an NO donor could be explained by two alternative hypotheses. If NO directly targets pendrin-mediated Cl Ϫ absorption, NO donors might not reduce Cl Ϫ absorption because the targeted transporter (pendrin) is absent in these mutant mice. However, if NO directly targets benzamil-sensitive Cl Ϫ absorption, rather than pendrin-mediated transport, NO donors would not reduce Cl Ϫ absorption because ENaC is already markedly downregulated in kidneys from pendrin-null mice (12) , and therefore 
NO does not reduce Cl
DISCUSSION
NO is an important blood pressure regulator. With NO depletion, hypertension is observed in both rodents (16) and people (49) . The present and previous studies showed that NO modulates blood pressure, in part, by targeting ENaC in the kidney. NO is produced through the action of NOS, which catalyze the oxidation of L-arginine to NO and L-citrulline (47, 51) . Three NOS isoenzymes have been identified: neuronal NOS (nNOS, NOS 1), inducible NOS (iNOS, NOS II), and endothelial NOS (eNOS, NOS III) (47) . eNOS (NOS III) expression has not been observed in the CCD. Within that segment, principal cells express nNOS (or NOS1) and ENaC (45) , whereas type A and type B intercalated cells express iNOS, but do not express ENaC (2, 36) . While the present study demonstrated that benzamil-sensitive Cl Ϫ absorption is reduced by endogenous NO production, which NOS are responsible for this NO production remains to be determined. The ENaC might be targeted by NO produced in principal cells. However, NO produced in other cells might act on principal cells through a paracrine effect.
NO is a hydrophobic compound that partitions from the aqueous phase into biological membranes (22) . By virtue of its biophysical properties, NO freely diffuses across artificial bilayers at a rate inversely proportional to the cholesterol content of the membrane (22) . Since NO can be transported by water channels, such as aquaporin-1 (AQP1) (8, 9) and AQP4 (46), we cannot exclude the possibility that NO traverses cell membranes in the mouse CCD through a mechanism other than diffusion.
While (26) .
The present study demonstrates that in aldosterone-treated mice, benzamil-sensitive Cl Ϫ transport is a major target of NO. Therefore, NO reduces amiloride (benzamil)-sensitive Na ϩ (33) and Cl Ϫ absorption in the CCD. These data raise the possibility that the NO depletion that follows aldosterone administration contributes to the increase in benzamil-sensitive transport observed during this treatment model.
While NO does not modulate pendrin-dependent Cl Ϫ absorption in vitro, NO modulates pendrin total protein abundance in vivo and in vitro (35, 40) . We observed that in NaCl-restricted mice, the angiotensin type 1 receptor modulates pendrin protein abundance through a mechanism that is dependent on NO (40) . The present study shows that while NO reduces Cl Ϫ absorption in the CCD, it does so independent of pendrin. Thus, NO changes the number of pendrin transporters, and possibly pendrin-mediated Cl Ϫ transport, in a span of hours to days, whereas NO changes pendrin-independent, ENaC-dependent Cl Ϫ absorption within 10 min. In summary, NO reduces benzamil-sensitive Cl Ϫ absorption in the mouse CCD. The downstream signaling cascade mediating NO-induced ENaC inhibition remains to be determined.
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